Scope:
• Annualized market data for the immunoglobulin
market from 2006 to 2012 and forecast to 2019
• Analysis of the seven key therapeutic segments: Primary Immunodeficiency
(PI), Chronic
Inflammatory Demyelinating Polyneuropathy (CIDP),
Multifocal
Motor Neuropathy (MMN), Myasthenia Gravis
(MG), Chronic
Lymphocytic Leukemia (CLL), Guillain-Barré Syndrome
(GBS) and
Idiopathic Thrombocytopenic Purpura (ITP).
• Analysis
of the immunoglobulins markets in the leading global geographies:
the US, the top five European countries, and Japan
• Market characterization of the immunoglobulin
market, covering size, revenue analysis by geography, annual cost
of therapy, and epidemiology
• Key drivers and barriers that have a significant
impact on the market
• Coverage of key marketed products, approved
indications, and safety and efficacy profiles
• Coverage of the pipeline molecules in various
phases of drug development
• Competitive
profiling of the leading companies: Baxter, Biotest, Bio Products
Laboratory, CSL Behring, Grifols, and Octapharma
• Key M&A activity and licensing agreements
between 2012 and mid-2013 in the global immunoglobulin market
• Overview of the immunoglobulin markets in
Asia-Pacific and China, covering regulations, key players and
marketed products
|
No comments:
Post a Comment